1990—2021年中国类风湿关节炎疾病负担趋势分析

doi:10.19485/j.cnki.issn2096-5087.2025.01.006

预防医学

2025, Vol. 37

Issue (1): 26-30 DOI: 10.19485/j.cnki.issn2096-5087.2025.01.006

论著

本期目录 | 过刊浏览 | 高级检索

1990—2021年中国类风湿关节炎疾病负担趋势分析

温佳鑫, 蒋俊鹏, 冯敏, 沈晓晨, 李晓印

苏州市姑苏区疾病预防控制中心,江苏苏州 215000

Trend in burden of rheumatoid arthritis in China from 1990 to 2021

WEN Jiaxin, JIANG Junpeng, FENG Min, SHEN Xiaochen, LI Xiaoyin

Gusu District Center for Disease Control and Prevention, Suzhou, Jiangsu 215000, China

摘要
参考文献
相关文章
Metrics

全文: PDF(1076 KB)
输出: BibTeX | EndNote (RIS)

摘要目的了解1990—2021年中国类风湿关节炎（RA）疾病负担变化趋势,为减轻RA疾病负担提供依据。方法收集全球疾病负担研究2021年资料,采用发病率、死亡率和伤残调整寿命年（DALY）率分析1990—2021年中国RA疾病负担,并与全球、不同社会人口指数（SDI）地区进行比较。采用平均年度变化百分比（AAPC）分析RA疾病负担变化趋势。结果中国RA粗发病率从1990年的10.87/10万上升至2021年的17.38/10万,粗死亡率从0.41/10万上升至0.72/10万,粗DALY率从34.26/10万上升至58.61/10万,增幅分别为59.98%、77.95%和71.06%。1990—2021年中国RA标化发病率呈上升趋势（AAPC=0.545%,P<0.05）,标化死亡率呈下降趋势（AAPC=-0.783%,P<0.05）,标化DALY率未见明显变化趋势（AAPC=-0.017%,P>0.05）。2021年女性RA标化发病率、标化死亡率和标化DALY率均高于男性;1990—2021年女性RA标化DALY率呈下降趋势（AAPC=-0.200%,P<0.05）,而男性呈上升趋势（AAPC=0.316%,P<0.05）。2021年RA粗发病率随年龄增长先上升后下降,75~<80岁组达最高,为34.36/10万;粗死亡率和粗DALY率均随年龄增长而上升,≥95岁组达最高,分别为26.72/10万和285.67/10万。与全球及不同SDI地区比较,2021年中国RA标化发病率和标化DALY率仅低于高SDI地区,标化死亡率低于中低SDI地区。结论 1990—2021年中国RA疾病负担呈上升趋势,与不同SDI地区相比处于较高水平;女性和老年人的RA疾病负担较重。

	服务

	把本文推荐给朋友
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	温佳鑫
	蒋俊鹏
	冯敏
	沈晓晨
	李晓印

关键词 ：类风湿关节炎, 疾病负担, 平均年度变化百分比

Abstract：Objective To analyze the trend in burden of rheumatoid arthritis (RA) in China from 1990 to 2021, so as to provide insights into reducing the RA burden in China. Methods Data of Global Burden of Disease Study 2021 were collected, and the incidence, mortality and disability-adjusted life years (DALY) of RA in China from 1990 to 2021 were analyzed and compared with global and different Socio-demographic Index (SDI) regions. The trend in burden of RA was analyzed using average annual percent change (AAPC). Results The crude incidence rates of RA in China increased from 10.87/10⁵ in 1990 to 17.38/10⁵ in 2021, the crude mortality rates increased from 0.41/10⁵ to 0.72/10⁵, and the crude DALY rates increased from 34.26/10⁵ to 58.61/10⁵, with the increases of 59.98%, 77.95% and 71.06%, respectively. From 1990 to 2021, the standardized incidence rates of RA in China showed an increasing trend (AAPC=0.545%, P<0.05), the standardized mortality rates showed a decreasing trend (AAPC=-0.783%, P<0.05), and the standardized DALY rates showed no significant trend (AAPC=-0.017%, P>0.05). In 2021, the standardized incidence rate, standardized mortality rate and standardized DALY rate of RA were higher in females than in males; from 1990 to 2021, the standardized DALY rates of RA showed a decreasing trend in females (AAPC=-0.200%, P<0.05) and an increasing trend in males (AAPC=0.316%, P<0.05). The crude incidence rates of RA first increased and then decreased with age in 2021, reaching the highest in the age group of 75-<80 years at 34.36/10⁵. Both the crude mortality rates and the crude DALY rates increased with age, reaching the highest in the age group of 95 years and older at 26.72/10⁵ and 285.67/10⁵, respectively. The standardized incidence rates and standardized DALY rates of RA in China in 2021 were lower than those in high SDI regions, while the standardized mortality rate was lower than that in medium-low SDI regions. Conclusions The burden of RA in China from 1990 to 2021 showed an upward trend, and was at a high level compared to different SDI regions. Higher disease burden of RA was seen in females and the elderly.

Key words： rheumatoid arthritis disease burden average annual percent change

收稿日期: 2024-08-16 修回日期: 2024-10-05 出版日期: 2025-01-10

中图分类号:

R181

作者简介: 温佳鑫,硕士,医师,主要从事流行病卫生应急工作

通信作者: 李晓印,E-mail：943269431@qq.com

引用本文:

温佳鑫, 蒋俊鹏, 冯敏, 沈晓晨, 李晓印. 1990—2021年中国类风湿关节炎疾病负担趋势分析[J]. 预防医学, 2025, 37(1): 26-30.
WEN Jiaxin, JIANG Junpeng, FENG Min, SHEN Xiaochen, LI Xiaoyin. Trend in burden of rheumatoid arthritis in China from 1990 to 2021. Preventive Medicine, 2025, 37(1): 26-30.

链接本文:

http://www.zjyfyxzz.com/CN/10.19485/j.cnki.issn2096-5087.2025.01.006 或 http://www.zjyfyxzz.com/CN/Y2025/V37/I1/26

[1] 中华医学会风湿病学分会.2018中国类风湿关节炎诊疗指南[J].中华内科杂志,2018,57(4):242-251.
Chinese Rheumatology Association.2018 Chinese guideline for the diagnosis and treatment of rheumatoid arthritis[J].Chin J Intern Med,2018,57(4):242-251.(in Chinese)
[2] 孙学菁,王丽芹,高兆虹,等.类风湿关节炎患者运动自我效能在社会支持与运动恐惧间的中介效应分析[J].预防医学,2024,36(5):378-382.
SUN X J,WANG L Q,GAO Z H,et al.Mediating effect of self-efficacy for exercise on social support and kinesiophobia in patients with rheumatoid arthritis[J].China Prev Med J,2024,36(5):378-382.(in Chinese)
[3] GBD 2021 Rheumatoid Arthritis Collaborators.Global,regional,and national burden of rheumatoid arthritis,1990-2020,and projections to 2050:a systematic analysis of the Global Burden of Disease Study 2021BD 2021 Rheumatoid Arthritis Collaborators.Global,regional,and national burden of rheumatoid arthritis,1990-2020,and projections to 2050:a systematic analysis of the Global Burden of Disease Study 2021[J].Lancet Rheumatol,2023,5(10):594-610.
[4] TIAN X P,LI M T,ZENG X F.The current status and challenges in the diagnosis and treatment of rheumatoid arthritis in China:an annual report of 2019[J].Rheumatol Immunol Res,2021,2(1):49-56.
[5] XIE W H,YANG X L,ZHANG Z L.The plight and light of treating rheumatoid arthritis in China[J].Lancet Rheumatol,2019,1(2):81-82.
[6] HU H,LUAN L,YANG K Q,et al.Burden of rheumatoid arthritis from a societal perspective:a prevalence-based study on cost of this illness for patients in China[J].Int J Rheum Dis,2018,21(8):1572-1580.
[7] GBD 2021 Diseases and Injuries Collaborators.Global incidence,prevalence,years lived with disability(YLDs),disability-adjusted life-years(DALYs),and healthy life expectancy(HALE)for 371 diseases and injuries in 204 countries and territories and 811 subnational locations,1990-2021:a systematic analysis for the Global Burden of Disease Study 2021[J].Lancet,2024,403(10440):2133-2161.
[8] 国家统计局.中国统计年鉴[EB/OL].[2024-10-05].https://www.stats.gov.cn/sj/ndsj.
[9] 甘雨舟,李茹.甲氨蝶呤治疗类风湿关节炎的跌宕历程[J].中华风湿病学杂志,2018,22(1):34-35.
GAN Y Z,LI R.The turbulent journey of methotrexate in the treatment of rheumatoid arthritis[J].Chin J Rheumatol,2018,22(1):34-35.(in Chinese)
[10] 赵艳荣,邱银伟,杨清,等.浙江省社区健康管理老年人慢性病患病现况研究[J].预防医学,2017,29(3):217-220,225.
ZHAO Y R,QIU Y W,YANG Q,et al.A study on the prevalence of chronic diseases and risk factors control among the elderly of community health management in Zhejiang Province[J].China Prev Med J,2017,29(3):217-220,225.(in Chinese)
[11] XING E,BILLI A C,GUDJONSSON J E.Sex bias and autoimmune diseases[J].J Invest Dermatol,2022,142(3 Pt B):857-866.
[12] FINCKH A,GILBERT B,HODKINSON B,et al.Global epidemiology of rheumatoid arthritis[J].Nat Rev Rheumatol,2022,18(10):591-602.
[13] ISLANDER U,JOCHEMS C,LAGERQUIST M K,et al.Estrogens in rheumatoid arthritis:the immune system and bone[J].Mol Cell Endocrinol,2011,335(1):14-29.
[14] HASSEN N,LACAILLE D,XU A,et al.National burden of rheumatoid arthritis in Canada,1990-2019:findings from the Global Burden of Disease Study 2019-a GBD collaborator-led study[J/OL].RMD Open,2024,10(1)[2024-10-05].http://doi.org/10.1136/rmdopen-2023-003533.
[15] MOUSAVI S E,NEJADGHADERI S A,KHABBAZI A,et al.The burden of rheumatoid arthritis in the Middle East and North Africa region,1990-2019[J/OL].Sci Rep,2022,12[2024-10-05].https://doi.org/10.1038/s41598-022-22310-0.
[16] 林进,徐丹怡.重视老年类风湿关节炎诊治[J].中华风湿病学杂志,2017,21(12):859-861.
LIN J,XU D Y.Emphasis on the diagnosis and treatment of rheumatoid arthritis in the elderly[J].Chin J Rheumatol,2017,21(12):859-861.(in Chinese)
[17] 李煜楠,徐鹏程,贾俊亚,等.体质指数与25种自身免疫性疾病的孟德尔随机化研究[J].预防医学,2024,36(5):388-392.
LI Y N,XU P C,JIA J Y,et al.Mendelian randomization study on body mass index and 25 types of autoimmune diseases[J].China Prev Med J,2024,36(5):388-392.(in Chinese)
[18] YAMAMOTO S S,YACYSHYN E,JHANGRI G S,et al.Household air pollution and arthritis in low-and middle-income countries:cross-sectional evidence from the World Health Organization's study on Global Ageing and Adult Health[J/OL].PLoS One,2019,14(12)[2024-10-05].http://doi.org/10.1371/journal.pone.0226738.
[19] 赵晴晴,丛舒,樊静,等.2019—2020年中国40岁及以上人群吸烟状况分析[J].中华流行病学杂志,2023,44(5):735-742.
ZHAO Q Q,CONG S,FAN J,et al.Prevalence of smoking in adults aged 40 years and above in China,2019-2020[J].Chin J Epidemiol,2023,44(5):735-742.(in Chinese)
[20] World Health Organization.Air pollution in China[EB/OL].[2024-10-05].https://www.who.int/china/zh/health-topics/air-pollution.

[1]	章群, 王永, 陈洁平, 包凯芳, 冯玥溢, 王小丽. 2011—2023年宁波市前列腺癌发病和死亡趋势分析[J]. 预防医学, 2025, 37(1): 46-50.
[2]	叶振淼, 樊丽辉, 郑宇航, 姜雪霞, 李慧君, 张默涵, 谢轶敏, 罗永园, 金茜. 温州市乳腺癌死亡及减寿分析[J]. 预防医学, 2024, 36(9): 746-749.
[3]	陈江, 齐小娟, 陈莉莉, 鲁琴宝, 王绩凯, 周标. 浙江省非伤寒沙门菌和副溶血性弧菌急性胃肠炎疾病负担[J]. 预防医学, 2024, 36(9): 755-759.
[4]	孙学菁, 王丽芹, 高兆虹, 邸之悦. 类风湿关节炎患者运动自我效能在社会支持与运动恐惧间的中介效应分析[J]. 预防医学, 2024, 36(5): 378-382.
[5]	叶振淼, 樊丽辉, 郑宇航, 张默涵, 姜雪霞, 罗永园, 谢轶敏, 金茜, 李慧君. 2014—2022年温州市肝癌死亡趋势分析[J]. 预防医学, 2024, 36(5): 393-396.
[6]	陈淑淑, 龚巍巍, 关云琦, 周晓燕, 潘劲, 戴品远, 王浩, 李娜, 俞敏. 1990—2019年浙江省结直肠癌疾病负担和危险因素分析[J]. 预防医学, 2024, 36(3): 203-206.
[7]	李嘉怡, 赵欣羽, 刘沁娴, 宁祖乐, 杜进林. 1990—2019年中国35岁以下人群白血病疾病负担趋势[J]. 预防医学, 2024, 36(12): 1022-1027.
[8]	曹婉婷, 胡秀兰, 韩荣荣. 2014—2023年临平区脑卒中疾病负担趋势[J]. 预防医学, 2024, 36(11): 988-991,995.
[9]	赵芳芳, 林君英, 王冬飞, 李玉荣, 高媛媛, 蒋园园. 萧山区恶性肿瘤死亡趋势分析[J]. 预防医学, 2024, 36(1): 78-81, 85.
[10]	张铁威, 张艳, 刘冰, 秦康, 李标, 徐珏. 2013—2021年杭州市糖尿病死亡及疾病负担分析[J]. 预防医学, 2023, 35(9): 752-756.
[11]	何晓庆, 罗进斌, 陈强, 魏芳. 2009—2021年金华市职业性尘肺病疾病负担分析[J]. 预防医学, 2023, 35(7): 620-624.
[12]	崔俊鹏, 陆艳, 黄春妍, 华钰洁, 王临池. 2007—2021年苏州市女性乳腺癌死亡与减寿分析[J]. 预防医学, 2023, 35(5): 380-383.
[13]	马昭君, 李伟伟, 董建梅, 周金意, 韩仁强, 秦绪成. 1990—2019年江苏省白血病疾病负担分析[J]. 预防医学, 2023, 35(4): 282-285,290.
[14]	周洁, 谭自明, 茹凉. 1990年与2019年中国0~14岁儿童肿瘤疾病负担分析[J]. 预防医学, 2023, 35(3): 205-209.
[15]	秦敏晔, 邱晶, 王洵之, 赵丽霞, 陆艳. 2006—2022年张家港市60岁及以上居民前列腺癌疾病负担分析[J]. 预防医学, 2023, 35(12): 1080-1083, 1088.

Viewed

Full text

Abstract

Cited

Shared

Discussed